SelectQuote will effect a 1-for-20 reverse stock split effective 11:59 p.m. Eastern Time on November 16, 2026, with split-adjusted trading starting November 17, 2026, to regain NYSE compliance.
SLQT · SelectQuote, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 59%
- Last earnings
- Nov 4, 2026
- Latest filing
- 10-Q · Nov 4
- Price history
- May 2020 to Nov 2026
Up next
Latest documents
SelectQuote posted Fiscal 1Q revenue of $280 million, down 15%, and an adjusted EBITDA loss of $17 million, more than $15 million better year over year. Operating cash flow guidance remained at least $60 million for fiscal 2027.
SelectQuote, Inc. reported that revenue declined 15% for the three months ended September 30, 2026, while net loss narrowed.
SelectQuote reported fiscal 2027 first-quarter revenue of $280.0 million versus $328.8 million and Adjusted EBITDA of $(17.0) million versus $(32.1) million. Fiscal 2027 guidance calls for revenue of $1.35 billion to $1.45 billion and Adjusted EBITDA of $90 million to $115 million.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q4 FY26 earnings call · Aug 25, 2026TL;DR. SelectQuote improved fiscal 2026 operating cash flow by $44 million, expects fiscal 2027 operating cash flow to approximately double to over $60 million, and targets over $30 million of annual savings while forecasting margin expansion. Fiscal 2026 adjusted EBITDA declined, fiscal 2027 revenue and adjusted EBITDA are guided lower, and the fourth quarter produced lower revenue, a net loss, and operating cash use.
- + Technology-enabled efficiencies are expected to produce over $30 million of annual expense savings for fiscal 2027.
- + Fiscal 2027 guidance anticipates approximately 60 basis points of consolidated adjusted EBITDA margin expansion despite lower year-over-year adjusted EBITDA.
- + Healthcare Services exited fiscal 2026 at an annual adjusted EBITDA run rate of nearly $50 million.
- + Healthcare Services revenue increased 14% to $844.935 million in fiscal 2026.
- − Healthcare Services membership is expected to moderate in the first quarter of fiscal 2027 before finishing the year around fiscal 2026 levels.
- − The Life segment faces a competitive term market and customer-acquisition costs that require monitoring.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA Margin per MA/MS policy non-GAAP | 13% | twelve months ended September 30, 2026 | — |
| Adjusted EBITDA per MA/MS policy non-GAAP | $333 | the twelve months ended September 30, 2026 | +9.2% |
|
|
|||
| Approved Medicare Advantage policies | 50,976 | the first quarter of fiscal year 2027 (three months ended Septem | — |
|
|
|||
| Final Expense Premiums | 20.06M | the three months ended September 30, 2026 | — |
|
|
|||
| Lifetime value of commissions per approved policy - All other | $161 | the three months ended September 30, 2026 | — |
|
|
|||
| Lifetime value of commissions per approved policy - Medicare Advantage | $890 | the three months ended September 30, 2026 | — |
| MA and MS approved policies | 558,128 | the twelve months ended September 30, 2026 | -2.0% |
|
|
|||
| MA and MS commission per MA / MS policy | $888 | twelve months ended September 30, 2026 | +1.5% |
|
|
|||
| Medicare Advantage submitted policies | 54,459 | the three months ended September 30, 2026 | — |
|
|
|||
| Other commission per MA/MS policy | $9 | twelve months ended September 30, 2026 | -10.0% |
|
|
|||
| Other revenue per MA/MS policy | $144 | twelve months ended September 30, 2026 | -4.6% |
|
|
|||
| Pharmacy revenue per MA/MS policy | $1,427 | twelve months ended September 30, 2026 | -2.1% |
|
|
|||
| Prescriptions Per Day | 28,139 | the three months ended September 30, 2026 | — |
|
|
|||
| Profitability per SelectRx member | $107.6 | the three months ended September 30, 2026 | — |
| SelectRx members | 99,753 | as of September 30, 2026 | — |
| Term Premiums | 18.45M | the three months ended September 30, 2026 | — |
|
|
|||
| Total approved policies | 59,410 | the three months ended September 30, 2026 | — |
|
|
|||
| Total operating expenses per MA / MS policy | -$2,135 | twelve months ended September 30, 2026 | — |
|
|
|||
| Total premiums | 38.51M | the three months ended September 30, 2026 | — |
| Total revenue per MA / MS policy | $2,468 | the twelve months ended September 30, 2026 | -1.0% |
|
|
|||
| Total submitted policies | 66,494 | the three months ended September 30, 2026 | — |
|
|
|||
| Trailing-twelve-month Adjusted EBITDA non-GAAP | $157M | Trailing-twelve-month | — |
| Adjusted EBITDA non-GAAP | $109.1M | fiscal year 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net income (loss) $62.19M
+$14.86M Share-based compensation expense
+$2.11M Transaction costs
+$17.49M Depreciation and amortization
+$0K Loss on disposal of property, equipment, and software, net
+$1M Impairment of equity-method investment
+$0K Impairment of long-lived asset
+$8.66M Loss on extinguishment of debt
-$55.8M Change in fair value of warrants
+$44.53M Interest expense, net
+$14.1M Income tax expense
= Adjusted EBITDA $109.13M
|
|||
| Adjusted Segment EBITDA non-GAAP | $200.52M | Year Ended June 30, 2026 filing | -6.2% |
|
|
|||
| Approved policies - All other | 71,298 | Year Ended June 30, 2026 | — |
| Healthcare Services Adjusted EBITDA Margin non-GAAP | 3% | Year Ended June 30, 2026 | — |
| Submitted policies - All other | 90,253 | Year Ended June 30, 2026 | — |
| Total Life Premiums | $185.16M | Year Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Insurance Brokers — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SLQT
this stock
SelectQuote, Inc.
|
$44.95M | — | +6.0% | — | 1.2% |
|
MRSH
Marsh & Mclennan Companies, Inc.
|
$98.06B | +11.2% | +10.3% | 24.7 | 1.3% |
|
AJG
Arthur J. Gallagher & Co.
|
$71.60B | +7.9% | +10.1% | 42.7 | 3.0% |
|
AON
Aon plc
|
$70.66B | -5.6% | +7.7% | 18.2 | 1.8% |
|
WTW
Willis Towers Watson PLC
|
$30.52B | +0.7% | -2.2% | 20.3 | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 16, 2026
- This year
- 14
SelectQuote will effect a 1-for-20 reverse stock split effective 11:59 p.m. Eastern Time on November 16, 2026, with split-adjusted trading starting November 17, 2026, to regain NYSE compliance.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SLQT | -43.3% | -18.4% | -75.7% | -29.8% | -82.2% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | -34.8% | -9.2% | -66.5% | -21.1% | -83.4% |